Ophthalmic treatment systems and methods of using the systems are disclosed. The ophthalmic treatment systems include (a) a light source device; (b) at least one optical treatment head operatively coupled to the light source device, comprising a light source array, and providing at least one treatment light; and (c) a light control device, which (i) provides patterned or discontinuous treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye); or (ii) adjusts intensity of part or all of the light source array, providing adjusted intensity treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye). The at least one treatment light promotes corneal and/or scleral collagen cross-linking.

An organometallic compound represented by Formula 1:

##STR00001## wherein in Formula 1, groups and variables are the same as described in the specification.

Ophthalmic treatment systems and methods of using the systems are disclosed. The ophthalmic treatment systems include (a) a light source device; (b) at least one optical treatment head operatively coupled to the light source device, comprising a light source array, and providing at least one treatment light; and (c) a light control device, which (i) provides patterned or discontinuous treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye); or (ii) adjusts intensity of part or all of the light source array, providing adjusted intensity treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye). The at least one treatment light promotes corneal and/or scleral collagen cross-linking.

Compounds, systems, and methods are provided for the design and assembly of a non-invasive, analyte sensing dressing. The dressing can be therapeutic. The dressing includes a sensor and a matrix. The sensor is capable of detecting analytes such as molecular oxygen, carbon dioxide, nitric oxides, dissolved analytes in plasma, and hydrogen ions. The matrix is at least partially permeable to the analyte. The device emits a detectable signal when the sensor is excited in the presence of the analyte. In one version of the dressing, the sensor includes a meso-unsubstituted metallated porphyrin that is sensitive towards oxygen. The metallated porphyrin can be excited when illuminated at a first wavelength, followed by emission of phosphorescence at a second wavelength whose intensity can be used as an indicator for oxygen concentration.

This disclosure relates to the field of fluorescent dyes, and in particular, compositions and methods for increasing fluorescent signals and the reduction of fluorescent quenching.

A bioprobe for a non-invasive diagnosis of Parkinson's disease triggered by an intestinal microenvironment, a preparation method thereof and use thereof are provided. The preparation method for the bioprobe provided by the present invention includes the following steps: (1) mixing europium nitrate with an organic ligand, and synthesizing a luminescent metal organic framework by a solvothermal method; (2) subjecting gold nanoparticles to a mixing reaction with aptamers to obtain Au-aptamer complexes; and (3) dissolving the luminescent metal organic framework in an Au-aptamer complex solution for a reaction, and washing the reaction product sequentially with deionized water, an ethanol solution, and a sodium dodecyl sulfate solution after the reaction to obtain the bioprobe. The present non-invasive oral bioprobe based on an intestinal microenvironment is configured for diagnosis of Parkinson's disease at an early stage.

Provided herein are room-temperature phosphorescence nanoparticles, methods of preparing the same, and uses of the same.

This disclosure relates to the field of fluorescent dyes, and in particular, compositions and methods for increasing fluorescent signals and the reduction of fluorescent quenching.

This disclosure relates to the field of fluorescent dyes, and in particular, compositions and methods for increasing fluorescent signals and the reduction of fluorescent quenching.

The present invention provides a luminogenic, in particular a phosphorogenic transition metal-based pyridyl complex containing a nitrone moiety, which nitrone moiety acts as a bioorthogonal functional group and an emission quencher, and can undergo cycloaddition reaction with a complementary bioorthogonal functional group coupled to a substrate. The transition metal is can be selected from iridium or ruthenium. Also disclosed is a method for preparing the transition metal-based pyridyl complex and a pharmaceutical composition comprising it. Still further provided is a method for bioorthogonal labeling of a biomolecule, a method for staining of a cell structure, a method for in vivo imaging of an organism, and a kit for in vivo imaging of an organism. The luminogenic properties and high reactivity of the complexes are highly advantageous for bioorthogonal labeling and imaging of biomolecules in their native biological environments at much lower costs than those of the existing commercial products.